Evidence map›Paper›PMID 34512504›Full record

ArticleFrontiers in neurology2021

Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.

Farzad Fatehi, Kamyar Moradi, Ali Asghar Okhovat, Ghazaleh Shojatalab, Behnaz Sedighi, Reza Boostani, Payam Sarraf, Bahram Haghi Ashtiani, Majid Ghasemi, Soussan Moussavi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Rituximab treatment in myasthenia gravis.Frontiers in neurology · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Farzad FatehiNeurology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Kamyar MoradiNeurology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ali Asghar OkhovatNeurology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ghazaleh ShojatalabNeurology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Behnaz SedighiNeurology Department, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Reza BoostaniNeurology Department, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Payam SarrafNeurology Department, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Bahram Haghi AshtianiDepartment of Neurology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Majid GhasemiDepartment of Neurology, Kashani Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Soussan MoussaviMedical Student, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Nassim AnjidaniHead of Medical Department, Orchid Pharmed Company, Tehran, Iran.
Shahriar NafissiNeurology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRShariati Hospital · IRFiroozgar General Hospital · IRGhaem Hospital · IRIsfahan University of Medical Sciences · IRKerman University of Medical Sciences · IRMashhad University of Medical Sciences · IRSina Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical responsemyasthenia gravisrefractoryrituximabzytux TM

Identifiers

PMID34512504
PMCPMC8427762
OpenAlexW3198877012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.